Management of recurrent vulvo-vaginal candidosis as a chronic illness

Gynecologic and Obstetric Investigation

Volumn 70, Issue 4, 2010, Pages 306-321

  Donders, Gilbert G G ^a,b,c,d   Bellen, Gert ^a   Mendling, Werner ^e  

^a Femicare   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Regionaal Ziekenhuis Heilig Hart Tienen   (Belgium)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e Pathologisches Institut   (Germany)

Author keywords

Candida non albicans; Candidiasis; Candidosis; Vaginitis; Vaginosis; Vulvo vaginitis

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BORIC ACID; BUTACONAZOLE; CANDIDA ALBICANS VACCINE; CASPOFUNGIN; CRYSTAL VIOLET; ECONAZOLE; FLUCONAZOLE; FLUCYTOSINE; HORMONE; ITRACONAZOLE; KETOCONAZOLE; MEPARTRICIN; MICONAZOLE; NYSTATIN; PLACEBO; TERCONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; CAREGIVER; CHRONIC DISEASE; CLINICAL TRIAL; CONTRACEPTION; DIET; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; FUNGUS CULTURE; GENE AMPLIFICATION; GLUCOSE METABOLISM; HUMAN; HYGIENE; IMMUNITY; LIVER TOXICITY; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; SINGLE DRUG DOSE; TREATMENT RESPONSE; VAGINA; VULVOVAGINAL DISEASE;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS, VULVOVAGINAL; CHRONIC DISEASE; CLOTHING; CONTRACEPTIVE AGENTS, FEMALE; DIAGNOSIS, DIFFERENTIAL; DIETARY CARBOHYDRATES; DRUG RESISTANCE, FUNGAL; FEMALE; FEMININE HYGIENE PRODUCTS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNITY; MALE; RECURRENCE; SALIVA; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASES; VAGINA; VULVA;

EID: 78649707330     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314022     Document Type: Review

References (122)

1. Odds FC, Arai T, Disalvo AF, Evans EG, Hay RJ, Randhawa HS, Rinaldi MG, Walsh TJ: Nomenclature of fungal diseases: a report and recommendations from a Sub-Committee of the International Society for Human and Animal Mycology (ISHAM). J Med Vet Mycol 1992;30:1-10.
2. Reed BD, Zazove P, Pierson CL, Gorenflo DW, Horrocks J: Candida transmission and sexual behaviors as risks for a repeat episode of Candida vulvovaginitis. J Womens Health (Larchmt) 2003;12:979-989.
3. Spinillo A, Carratta L, Pizzoli G, Lombardi G, Cavanna C, Michelone G, Guaschino S: Recurrent vaginal candidiasis: results of a cohort study of sexual transmission and intestinal reservoir. J Reprod Med 1992;37:343-347.
4. Bisschop MP, Merkus JM, Scheygrond H, Van CJ: Co-treatment of the male partner in vaginal candidosis: a double-blind randomized control study. Br J Obstet Gynaecol 1986;93:79-81.
5. Fong IW: The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourin Med 1992;68:174-176.
6. Shihadeh AS, Nawafleh AN: The value of treating the male partner in vaginal candidiasis. Saudi Med J 2000;21:1065-1067.
7. Baeten JM, Nyange PM, Richardson BA, Lavreys L, Chohan B, Martin HL Jr, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, Kreiss JK: Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol 2001;185:380-385.
8. Sobel JD: Vulvovaginitis: when Candida becomes a problem. Dermatol Clin 1998;16:763-768, xii.
9. El-Din SS, Reynolds MT, Ashbee HR, Barton RC, Evans EG: An investigation into the pathogenesis of vulvo-vaginal candidosis. Sex Transm Infect 2001;77:179-183.
10. Donders G, Bellen G, Byttebier G, Verguts L, Hinoul P, Walckiers R, Stalpaert M, Vereecken A, Van EJ: Individualized decreasingdose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCi-DiF trial). Am J Obstet Gynecol 2008;199:613-619.
11. Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, Sperling M, Livengood C III, Horowitz B, Von TJ, Edwards L, Panzer H, Chu TC: Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004;351:876-883.
12. Hay P, Czeizel AE: Asymptomatic Trichomonas and Candida colonization and pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2007;21:403-409.
13. Pirotta MV, Garland SM: Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J Clin Microbiol 2006;44:3213-3217.
14. Donders GG, Larsson PG, Platz-Christensen JJ, Hallén A, van der Meijden W, Wölner-Hanssen P: Variability in diagnosis of clue cells, lactobacillary grading and white blood cells in vaginal wet smears with conventional bright light and phase contrast microscopy. Eur J Obstet Gynecol Reprod Biol 2009;145:109-112.
15. Sobel JD: Vulvovaginal candidosis. Lancet 2007;369:1961-1971.
16. Emmerson J, Gunputrao A, Hawkswell J, Dexter A, Sykes R, Searle S, Cross A, Nathan PM: Sampling for vaginal candidosis: how good is it? Int J STD AIDS 1994;5:356-358.
17. Passos MR, Varella RQ, Barreto NA, Garcia ML, Giraldo PC: Accuracy of a self-collection kit for the microbiological study of the vaginal content. Braz J Infect Dis 2007;11:249-253.
18. van de Wijgert J, Altini L, Jones H, de Kock A, Young T, Williamson AL, Hoosen A, Coetzee N: Two methods of self-sampling compared to clinician sampling to detect reproductive tract infections in Gugulethu, South Africa. Sex Transm Dis 2006;33:516-523.
19. Weissenbacher T, Witkin SS, Ledger WJ, Tolbert V, Gingelmaier A, Scholz C, Weissenbacher ER, Friese K, Mylonas I: Relationship between clinical diagnosis of recurrent vulvovaginal candidiasis and detection of Candida species by culture and polymerase chain reaction. Arch Gynecol Obstet 2009;279:125-129.
20. Lowe NK, Neal JL, Ryan-Wenger NA: Accuracy of the clinical diagnosis of vaginitis compared with a DNA probe laboratory standard. Obstet Gynecol 2009;113:89-95.
21. Nowakowska D, Gaj Z, Sobala W, Wilczynski J: Evaluation of susceptibility to antifungal agents of fungal strains isolated from pregnant women with diabetes and healthy pregnant women. Ginekol Pol 2009;80:274-279.
22. Looi CY, D'Silva EC, Seow HF, Rosli R, Ng KP, Chong PP: Increased expression and hotspot mutations of the multidrug efflux transporter, CDR1 in azole-resistant Candida albicans isolates from vaginitis patients. FEMS Microbiol Lett 2005;249:283-289.
23. Cernicka J, Subik J: Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis. Int J Antimicrob Agents 2006;27:403-408.
24. Pitsouni E, Iavazzo C, Falagas ME: Itraconazole vs. fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials. Am J Obstet Gynecol 2008;198:153-160.
25. Owen MK, Clenney TL: Management of vaginitis. Am Fam Physician 2004;70:2125-2132.
26. Ries AJ: Treatment of vaginal infections: candidiasis, bacterial vaginosis, and trichomoniasis. J Am Pharm Assoc (Wash) 1997; NS37:563-569.
27. Nurbhai M, Grimshaw J, Watson M, Bond C, Mollison J, Ludbrook A: Oral versus intravaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev 2007; CD002845.
28. De Seta F, Schmidt M, Vu B, Essmann M, Larsen B: Antifungal mechanisms supporting boric acid therapy of Candida vaginitis. J Antimicrob Chemother 2009;63:325-336.
29. Sobel JD, Chaim W, Nagappan V, Leaman D: Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003;189:1297-1300.
30. White DJ, Johnson EM, Warnock DW: Management of persistent vulvo-vaginal candidosis due to azole-resistant Candida glabrata. Genitourin Med 1993;69:112-114.
31. Stein GE, Mummaw NL, Schooley SL: Prevention of recurrent vaginal candidiasis with weekly terconazole cream. Ann Pharmacother 1996;30:1080-1083.
32. Balsdon MJ, Tobin JM: Recurrent vaginal candidosis: prospective study of effectiveness of maintenance miconazole treatment. Genitourin Med 1988;64:124-127.
33. Sobel JD: Recurrent vulvovaginal candidiasis: a prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med 1986;315:1455-1458.
34. Meyer H, Goettlicher S, Mendling W: Stress as a cause of chronic recurrent vulvovaginal candidosis and the effectiveness of the conventional antimycotic therapy. Mycoses 2006;49:202-209.
35. Ehrstrom SM, Kornfeld D, Thuresson J, Rylander E: Signs of chronic stress in women with recurrent Candida vulvovaginitis. Am J Obstet Gynecol 2005;193:1376-1381.
36. Fidel PL Jr: Immunity in vaginal candidiasis. Curr Opin Infect Dis 2005;18:107-111.
37. Barousse MM, Van der Pol BJ, Fortenberry D, Orr D, Fidel PL Jr: Vaginal yeast colonisation, prevalence of vaginitis, and associated local immunity in adolescents. Sex Transm Infect 2004;80:48-53.
38. Fidel PL Jr, Barousse M, Lounev V, Espinosa T, Chesson RR, Dunlap K: Local immune responsiveness following intravaginal challenge with Candida antigen in adult women at different stages of the menstrual cycle. Med Mycol 2003;41:97-109.
39. Fidel PL Jr, Ginsburg KA, Cutright JL, Wolf NA, Leaman D, Dunlap K, Sobel JD: Vaginalassociated immunity in women with recurrent vulvovaginal candidiasis: evidence for vaginal Th1-type responses following intravaginal challenge with Candida antigen. J Infect Dis 1997;176:728-739.
40. Neves NA, Carvalho LP, Lopes AC, Cruz A, Carvalho EM: Successful treatment of refractory recurrent vaginal candidiasis with cetirizine plus fluconazole. J Low Genit Tract Dis 2005;9:167-170.
41. Levy DA, Bohbot JM, Catalan F, Normier G, Pinel AM, Dussourd DL: Phase II study of D.651, an oral vaccine designed to prevent recurrences of vulvovaginal candidiasis. Vaccine 1989;7:337-340.
42. Liu F, Liao Q, Liu Z: Mannose-binding lectin and vulvovaginal candidiasis. Int J Gynaecol Obstet 2006;92:43-47.
43. IP W, Lau YL: Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. J Infect Dis 2005;190:632-640.
44. Lillegard JB, Sim RB, Thorkildson P, Gates MA, Kozel TR: Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo. J Infect Dis 2006;193:1589-1597.
45. Babula O, Lazdane G, Kroica J, Ledger WJ, Witkin SS: Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannosebinding lectin gene polymorphism in Latvian women. Clin Infect Dis 2003;37:733-737.
46. Donders GG, Babula O, Bellen G, Linhares IM, Witkin SS: Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. BJOG 2008;115:1225-1231.
47. Giraldo PC, Babula O, Goncalves AK, Linhares IM, Amaral RL, Ledger WJ, Witkin SS: Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol 2007;109:1123-1128. (Pubitemid 46685956)
48. Mardh PA, Wagstrom J, Landgren M, Holmen J: Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription. 2. Factors that may have influenced the marked changes in sales volumes during the 1990s. Infect Dis Obstet Gynecol 2004;12:99-108.
49. Mardh PA, Wagstrom J, Landgren M, Holmen J: Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription. I. Analyses of a unique database. Infect Dis Obstet Gynecol 2004;12:91-97.
50. Bauters TG, Dhont MA, Temmerman MI, Nelis HJ: Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 2002;187:569-574.
51. Cernicka J, Subik J: Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis. Int J Antimicrob Agents 2006;27:403-408.
52. Rahman KM, Chowdhury TA, Nahar N, Huq JA: General yeast infection in Bangladeshi women using contraceptives. Bangladesh Med Res Counc Bull 1984;10:65-70.
53. Otero L, Palacio V, Carreno F, Mendez FJ, Vazquez F: Vulvovaginal candidiasis in female sex workers. Int J STD AIDS 1998;9:526-530.
54. Omar AA: Gram stain versus culture in the diagnosis of vulvovaginal candidiasis. East Mediterr Health J 2001;7:925-934.
55. Ozcan SK, Budak F, Yucesoy G, Susever S, Willke A: Prevalence, susceptibility profile and proteinase production of yeasts causing vulvovaginitis in Turkish women. APMIS 2006;114:139-145.
56. Paulitsch A, Weger W, Ginter-Hanselmayer G, Marth E, Buzina W: A 5-year (2000-2004) epidemiological survey of Candida and non-Candida yeast species causing vulvovaginal candidiasis in Graz, Austria. Mycoses 2006;49:471-475.
57. Vermitsky JP, Self MJ, Chadwick SG, Trama JP, Adelson ME, Mordechai E, Gygax SE: Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection. J Clin Microbiol 2008;46:1501-1503.
58. al-Rawi N, Kavanagh K: Characterisation of yeasts implicated in vulvovaginal candidosis in Irish women. Br J Biomed Sci 1999;56:99-104.
59. Erdem H, Cetin M, Timuroglu T, Cetin A, Yanar O, Pahsa A: Identification of yeasts in public hospital primary care patients with or without clinical vaginitis. Aust NZ J Obstet Gynaecol 2003;43:312-316.
60. Geiger AM, Foxman B, Sobel JD: Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C glabrata and no candida. Genitourin Med 1995;71:304-307.
61. Sobel JD: Vulvovaginitis due to Candida glabrata. An emerging problem. Mycoses 1998;41(suppl 2):18-22.
62. Enweani IB, Ogbonna CI, Kozak W: The incidence of candidiasis amongst the asymptomatic female students of the University of Jos, Nigeria. Mycopathologia 1987;99:135-141.
63. Okungbowa FI, Isikhuemhen OS, Dede AP: The distribution frequency of Candida species in the genitourinary tract among symptomatic individuals in Nigerian cities. Rev Iberoam Micol 2003;20:60-63.
64. De Leon EM, Jacober SJ, Sobel JD, Foxman B: Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis 2002;2:1.
65. Duerr A, Sierra MF, Feldman J, Clarke LM, Ehrlich I, DeHovitz J: Immune compromise and prevalence of Candida vulvovaginitis in human immunodeficiency virus-infected women.
66. Mendling W: Torulopsis in gynecology. Geburtshilfe Frauenheilkd 1984;44:583-586;
67. Obstet Gynecol 1997;90:252-256.
68. Dhingra S, Roseblade CK: Boric acid for refractory Candida glabrata vaginitis. J Obstet Gynaecol 2006;26:584.
69. Ray D, Goswami R, Banerjee U, Dadhwal V, Goswami D, Mandal P, Sreenivas V, Kochupillai N: Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 2007;30:312-317.
70. Mendling W, Pinto De Andrade M, Gutschmidt J, Gantenberg R, Presber W, Schonian G: Strain specificity of yeasts isolated from different locations of women suffering from vaginal candidosis, and their partners. Mycoses 2000;43:387-392.
71. Lockhart SR, Reed BD, Pierson CL, Soll DR: Most frequent scenario for recurrent Candida vaginitis is strain maintenance with 'substrain shuffling': demonstration by sequential DNA fingerprinting with probes Ca3, C1, and CARE2. J Clin Microbiol 1996;34:767-777.
72. Bradshaw CS, Morton AN, Garland SM, Morris MB, Moss LM, Fairley CK: Higherrisk behavioral practices associated with bacterial vaginosis compared with vaginal candidiasis. Obstet Gynecol 2005;106:105-114.
73. Donders GG, Mertens I, Bellen G, Pelckmans S: Self-elimination of risk factors for recurrent vaginal candidosis. Mycoses 2009, electronically published ahead of print: MYC1754 [pii]; 10.1111/j.1439-0507.2009. 01754.x [doi]
74. Gertig DM, Kapiga SH, Shao JF, Hunter DJ: Risk factors for sexually transmitted diseases among women attending family planning clinics in Dar-es-Salaam, Tanzania. Genitourin Med 1997;73:39-43.
75. Geiger AM, Foxman B: Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology 1996;7:182-187.
76. Ginter G, Soyer HP, Rieger E: Vaginal yeast colonization and promiscuity: a study of 197 prostitutes. Mycoses 1992;35:177-180.
77. Fong IW: The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourin Med 1992;68:174-176.
78. Shihadeh AS, Nawafleh AN: The value of treating the male partner in vaginal candidiasis. Saudi Med J 2000;21:1065-1067.
79. Wilton L, Kollarova M, Heeley E, Shakir S: Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England. Drug Saf 2003;26:589-597.
80. Spinillo A, Capuzzo E, Nicola S, Baltaro F, Ferrari A, Monaco A: The impact of oral contraception on vulvovaginal candidiasis. Contraception 1995;51:293-297.
81. Spinillo A, Pizzoli G, Colonna L, Nicola S, De Seta F, Guaschino S: Epidemiologic characteristics of women with idiopathic recurrent vulvovaginal candidiasis. Obstet Gynecol 1993;81:721-727.
82. Daus AD, Hafez ES: Candida albicans in women. Nurs Res 1975;24:430-433.
83. Rohatiner JJ, Grimble A: Genital candidasis and oral contraceptives. J Obstet Gynaecol Br Commonw 1970;77:1013-1015.
84. Morris CA: Influence of oral contraceptives on the presence and persistence of Candida albicans and beta-haemolytic streptococci in the vagina. J Clin Pathol 1969;22:488-491.
85. Ceruti M, Canestrelli M, Condemi V, Piantelli G, De Paolis P, Amone F, Tovagliari D: Methods of contraception and rates of genital infections. Clin Exp Obstet Gynecol 1994;21:119-123.
86. Hart G: Factors associated with trichomoniasis, candidiasis and bacterial vaginosis. Int J STD AIDS 1993;4:21-25.
87. Birnbaum H, Kraussold E: Incidence of the Blastomyces and Trichomonad infections during the use of hormonal and intrauterine contraception. Zentralbl Gynäkol 1975;97:1636-1640.
88. Tarry W, Fisher M, Shen S, Mawhinney M: Candida albicans: the estrogen target for vaginal colonization. J Surg Res 2005;129:278-282.
89. Fosch S, Fogolin N, Azzaroni E, Pairetti N, Dana L, Minacori H, Tita I, Redona M, Gribaudo G: Vulvovaginitis: correlation with predisposing factors, clinical manifestations and microbiological studies. Rev Argent Microbiol 2006;38:202-205.
90. Beigi RH, Meyn LA, Moore DM, Krohn MA, Hillier SL: Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet Gynecol 2004;104:926-930.
91. Veres S, Miller L, Burington B: A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol 2004;104:555-563.
92. Parewijck W, Claeys G, Thiery M, van Kets H: Candidiasis in women fitted with an intrauterine contraceptive device. Br J Obstet Gynaecol 1988;95:408-410.
93. Hodoglugil NN, Aslan D, Bertan M: Intrauterine device use and some issues related to sexually transmitted disease screening and occurrence. Contraception 2000;61:359-364.
94. Karaer A, Boylu M, Avsar AF: Vaginitis in Turkish women: symptoms, epidemiologicmicrobiologic association. Eur J Obstet Gynecol Reprod Biol 2005;121:211-215.
95. De Oliveira JM, Cruz AS, Fonseca AF, Vaz CP, Rodrigues A, Aurea F, Maia J, Sousa JA: Prevalence of Candida albicans in vaginal fluid of asymptomatic Portuguese women. J Reprod Med 1993;38:41-42.
96. Horowitz BJ, Edelstein SW, Lippman L: Sugar chromatography studies in recurrent Candida vulvovaginitis. J Reprod Med 1984;29:441-443.
97. ®). Contraception 2010.
98. Reed BD, Slattery ML, French TK: The association between dietary intake and reported history of Candida vulvovaginitis. J Fam Pract 1989;29:509-515.
99. Donders GG, Prenen H, Verbeke G, Reybrouck R: Impaired tolerance for glucose in women with recurrent vaginal candidiasis. Am J Obstet Gynecol 2002;187:989-993.
100. Donders GG: Lower genital tract infections in diabetic women. Curr Infect Dis Rep 2002;4:536-539.
101. Ehrstrom S, Yu A, Rylander E: Glucose in vaginal secretions before and after oral glucose tolerance testing in women with and without recurrent vulvovaginal candidiasis. Obstet Gynecol 2006;108:1432-1437.
102. Ozkinay E, Terek MC, Yayci M, Kaiser R, Grob P, Tuncay G: The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections. BJOG 2005;112:234-240.
103. Hilton E, Isenberg HD, Alperstein P, France K, Borenstein MT: Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992;116:353-357.
104. Patel DA, Gillespie B, Sobel JD, Leaman D, Nyirjesy P, Weitz MV, Foxman B: Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: results of a prospective cohort study. Am J Obstet Gynecol 2004;190:644-653.
105. Edman J, Sobel JD, Taylor ML: Zinc status in women with recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 1986;155:1082-1085.
106. Jobst D, Kraft K: Candida species in stool, symptoms and complaints in general practice - a cross-sectional study of 308 outpatients. Mycoses 2006;49:415-420.
107. Raska M, Belakova J, Horynova M, Krupka M, Novotny J, Sebestova M, Weigl E: Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis. Med Mycol 2008;46:411-420.
108. Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C, Norelli F, Bellucci C, Polonelli L, Costantino P, Rappuoli R, Cassone A: A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 2005;202:597-606.
109. Mendling W, Koldovsky U: Investigations by cell-mediated immunologic tests and therapeutic trials with thymopentin in vaginal mycoses. Infect Dis Obstet Gynecol 1996;4:225-231.
110. Mendling W, Koldovsky U: Immunological investigations in vaginal mycoses. Mycoses 1996;39:177-183.
111. Altamura M, Casale D, Pepe M, Tafaro A: Immune responses to fungal infections and therapeutic implications. Curr Drug Targets Immune Endocr Metabol Disord 2001;1:189-197.
112. Cardenas-Freytag L, Steele C, Wormley FL Jr, Cheng E, Clements JD, Fidel PL Jr: Partial protection against experimental vaginal candidiasis after mucosal vaccination with heat-killed Candida albicans and the mucosal adjuvant LT (R192G). Med Mycol 2002;40:291-299.
113. De Bernardis F, Boccanera M, Adriani D, Girolamo A, Cassone A: Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis. Infect Immun 2002;70:2725-2729.
114. Han Y, Morrison RP, Cutler JE: A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun 1998;66:5771-5776.
115. Cassone A, Boccanera M, Adriani D, Santoni G, De Bernardis F: Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection. Infect Immun 1995;63:2619-2624.
116. Levy DA, Bohbot JM, Catalan F, Normier G, Pinel AM, Dussourd DL: Phase II study of D.651, an oral vaccine designed to prevent recurrences of vulvovaginal candidiasis. Vaccine 1989;7:337-340.
117. Waldman RH, Cruz JM, Rowe DS: Intravaginal immunization of humans with Candida albicans. J Immunol 1972;109:662-664.
118. Rigg D, Miller MM, Metzger WJ: Recurrent allergic vulvovaginitis: treatment with Candida albicans allergen immunotherapy. Am J Obstet Gynecol 1990;162:332-336.
119. Farage M, Bramante M, Otaka Y, Sobel J: Do panty liners promote vulvovaginal candidiasis or urinary tract infections? A review of the scientific evidence. Eur J Obstet Gynecol Reprod Biol 2007;132:8-19.
120. Elegbe IA, Botu M: A preliminary study on dressing patterns and incidence of candidiasis. Am J Public Health 1982;72:176-177.
121. Mardh PA, Novikova N, Stukalova E: Colonisation of extragenital sites by Candida in women with recurrent vulvovaginal candidosis. BJOG 2003;110:934-937.
122. Reed BD, Ford K, Wirawan DN: The Bali STD/AIDS study: association between vaginal hygiene practices and STDs among sex workers. Sex Transm Infect 2001;77:46-52.